RxDoctor Payments Data

Clifford Reed, MD

Neurology · West Reading, PANPI 1649281833

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $193,904 of the $310,966 with a category attached, or 62.4%. 36 manufacturers reported payments, led by EMD Serono, Inc. at 30.1% of the total. Reporting peaked in 2019 at $140,017 and has fallen 98.5% since, to $2,142 in 2025. Among neurology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$310,966in general payments, 2019–2025

Across 852 payments — averaging $364.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$94K
  • Biogen$69K
  • Sanofi$52K
  • Genentech USA, Inc.$46K
  • Bristol Myers Squibb$22K
  • Novartis$12K
  • plus $17K from 30 others
$573,068in research payments, 2019–2025

Across 18 payments — averaging $31,837 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$530K
  • EMD Serono, Inc.$40K
  • F. Hoffmann-la Roche AG$3K

What the payments were for

  • Consulting fees$47,41815%
  • Speaking & faculty fees$193,90462%
  • Travel & lodging$39,01813%
  • Food & beverage$30,28210%
  • Education$3430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$310,966 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$26,989
Medicare patients
174
Services billed
285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MavencladCladribine29$2,205,938
AubagioTeriflunomide78$776,452
Kesimpta PenOfatumumab59$630,526
EnspryngSatralizumab-Mwge13$227,753
Teriflunomide92$222,285
FingolimodFingolimod Hcl24$146,579
Avonex Pen (4 Pack)Interferon Beta-1a12$113,687
Aimovig AutoinjectorErenumab-Aooe140$107,900
CopaxoneGlatiramer Acetate16$87,899
Emgality PenGalcanezumab-Gnlm96$75,971
GlatopaGlatiramer Acetate22$45,684
Ajovy AutoinjectorFremanezumab-Vfrm47$44,259
Dalfampridine ErDalfampridine67$31,266
Nurtec OdtRimegepant Sulfate17$16,970
Carbamazepine148$10,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Mavenclad$93,526$2,205,93829 claims
SanofiAubagio$51,894$776,45278 claims
Genentech USA, Inc.Enspryng$45,918$227,75313 claims
Teva Pharmaceuticals USA, Inc.Copaxone$498$87,89916 claims
PfizerNurtec Odt$34$16,97017 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$28$1,26311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 941 neurology providers in Pennsylvania.

Other neurology in West Reading

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →